Business Wire

World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China.

14.11.2022 08:00:00 EET | Business Wire | Press release

Share

Late in 2021, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia Air™ utilizing Aerogen’s proprietary aerosol drug delivery technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221113005049/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Inhaled vaccine administration (Photo: Business Wire)

In 2022 Convidecia Air™ was granted Emergency Use Authorization as a booster dose by the National Medical Products Administration of China (“NMPA”). On October 25th, Shanghai became the first city to initiate booster vaccination by inhalation for adults aged 18 and above, who have previously been primed with two shots of inactivated vaccines or one shot of Convidecia™.

The aerosolised vaccine is directly inhaled via a cup dispenser into the patient’s airway. This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.

According to a Phase III clinical trial published in December 2021 in the journal The Lancet, the injected Convidecia™ vaccine was 91.7% effective at preventing severe disease after four weeks or longer following a single administered dose.1

Further clinical trials on delivery by inhalation, published in the Lancet in December 2021 and August 2022, demonstrated the inhaled vaccine Convidecia Air™ as a heterologous booster generated much stronger immune responses than those induced by a homologous inactivated vaccine booster. Convidecia Air™ has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observed. 2,3

Inoculation by the inhaled aerosol route requires a considerably smaller volume of vaccine to be used and therefore provides the capacity to allow a much larger number of patients to cost-effectively access the CanSinoBIO vaccine than would have been possible using an injectable approach.4

Further clinical trials of the inhaled vaccine are progressing in Asia and Latin America to support other country approvals for this innovative technology.

John Power, Aerogen CEO & Founder said “T he world has an urgent need for an effective, low-cost, globally scalable, and globally accessible solution to mass vaccination. The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with the capacity to vaccinate in the billions. We are delighted with the news of approval and public rollout in China and look forward to further approval of inhaled vaccines around the world.”

Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO commented; “We are delighted that our collaborative efforts with Aerogen on the innovative inhaled delivery of COVID-19 vaccine is recognized by the market. This significant breakthrough in vaccination has the potential of blocking transmission through an added layer of mucosal immunity. We look forward to expanding global access to our innovative needleless vaccine to accelerate the pace of bringing society back to life.”

Leo Clancy, CEO, Enterprise Ireland said: “Aerogen has an exceptional track record, delivering game-changing disruptive technology to MedTech and pharma companies throughout the world to optimise and accelerate the development and production of medicines, including vaccines. The innovative technologies pursued by the company continue to push boundaries and transform treatments, in this case with respect to Covid-19, positively impacting the well-being of people worldwide. Today’s announcement is hugely significant and further strengthens Ireland’s position in the global value chain of vaccine development and manufacturing. We look forward to continuing to work with Aerogen as it continues to transform product offering for healthcare through innovation, underpinning the company’s continued growth in world markets.”

Additional information:

About CanSinoBIO:

CanSinoBIO (SSE: 688185, HKEX: 06185) is a leading biopharmaceutical company committed to research, production, and commercialization of innovative vaccines for global public health security. It possesses five integrated platform technologies including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant VLP technology, mRNA vaccine technology as well as formulation and delivery technology. As of today, it has established a rich portfolio of pipeline products preventing 12 diseases, including Asia’s innovative vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) recognized by the WHO, and our global innovative inhaled COVID-19 vaccine Convidecia AirTM. Additional information can be found online at www.cansinotech.com.

About Aerogen:

Aerogen is the world leader in acute care aerosol drug delivery. The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology5 that mitigates the transmission of patient-generated infectious aerosol during ventilation6-11. As the only globally available closed-circuit system, Aerogen technology has been used to treat over 16 million patients in 75 countries worldwide, playing a critical role in emergency departments and intensive care units12.

References

  1. Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, Ikram A, Lanas F, Guerrero ML, Muñoz Navarro SR, Sued O, Lioznov DA, Dzutseva V, Parveen G, Zhu F, Leppan L, Langley JM, Barreto L, Gou J, Zhu T, for the CanSino COVID-19 Global Efficacy Study Group. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 2022 399: 237-248, DOI: doi.org/10.1016/S0140-6736(21)02753-7
  2. Li JX, Wu SP, Guo XL, Tang R, Huang BY, Chen XQ, Chen Y, Hou LH, Liu JX, Zhong J, Pan HX, Shi FJ, Xu XY, Li ZP, Zhang XY, Cui LB, Tan WJ, Chen W, Zhu FC. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med 2022, 10: 739-48. doi.org/10.1016/S2213-2600(22)00087-X
  3. Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, Wang B, Chen C, Chen Y, Song X, Wang Y, Si W. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis 2021, 21: 1654-64. doi.org/10.1016/ S1473-3099(21)00396-0
  4. Heida R, Hinrichs WL, Frijlink HW. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19 [published online ahead of print, 2021 Aug 25]. Expert Rev Vaccines. 2021;1-18
  5. Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Revision U.
  6. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir. Med. 2020; 167. doi:10.1016/j.rmed.2020.105987.
  7. Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID19 patients: A single center experience. J. Crit. Care. 2020; 58: 56–57.
  8. Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C et al. Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020. doi:10.1089/jamp.2020.1615.
  9. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. Am J Respir Crit Care Med 2020. doi:10.1164/rccm.202009-3533SO.
  10. O’Toole C, McGrath JA, Joyce M, Bennett G, Byrne MA, MacLoughlin R. Fugitive Aerosol Therapy Emissions during Mechanical Ventilation: In Vitro Assessment of the Effect of Tidal Volume and Use of Protective Filters. Aerosol Air Qual Res 2020; 20. doi:10.4209/aaqr.2020.04.0176.
  11. Joyce M, McGrath JA, Mac Giolla Eain M, O’Sullivan A, Byrne M, MacLoughlin R. Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation. Pharmaceutics 2021; 13: 199.
  12. Aerogen internal data on file.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information on Aerogen technology please contact:

D eclan Slemon, dslemon@aerogen.com

For further information about Aerogen in China please contact

D an Han, DHan@aerogen.com

For further information on CanSinoBIO please contact:

J unhong Jing, junhong.jing@cansinotech.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release

Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release

Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release

NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous

Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 19:40:00 EET | Press release

Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redundant Command and Data Handling systems as well as the Instrument Command and Data Handling systems for both the Wide Field Instrument and Coronagraph Instrum

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 17:05:00 EET | Press release

On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye